{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:25:26Z","timestamp":1778876726550,"version":"3.51.4"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10067-018-4373-y","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T18:58:52Z","timestamp":1542653932000},"page":"601-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy"],"prefix":"10.1007","volume":"38","author":[{"given":"Marie","family":"Tauber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Laly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Josselin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"issue":"1","key":"4373_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13(1):211","journal-title":"BMC Med"},{"issue":"8","key":"4373_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AMM, Soria JC, Mateus C, Robert C (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473\u2013486","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"4373_CR3","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","volume":"21","author":"JS Weber","year":"2016","unstructured":"Weber JS, Postow M, Lao CD, Schadendorf D (2016) Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21(10):1230\u20131240","journal-title":"Oncologist"},{"issue":"8","key":"4373_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, Andr\u00e9 T (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773\u2013777","journal-title":"J Clin Oncol"},{"issue":"10","key":"4373_CR5","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216\u20131222. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"issue":"4","key":"4373_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","volume":"41","author":"T Liewluck","year":"2018","unstructured":"Liewluck T, Kao JC, Mauermann ML (2018) PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother 41(4):208\u2013211","journal-title":"J Immunother"},{"issue":"2","key":"4373_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","volume":"151","author":"S Sheik Ali","year":"2015","unstructured":"Sheik Ali S, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, Vleugels RA (2015) Drug-associated dermatomyositis following Ipilimumab therapy. JAMA Dermatol 151(2):195\u2013199","journal-title":"JAMA Dermatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4373-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4373-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:29:52Z","timestamp":1574123392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4373-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["4373"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4373-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"2 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.TA was principal investigators in CheckMate 142 and is consultant for BMS and MSD Oncology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}